AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...
Toronto Life on MSN
The high price of hope: Inside Toronto’s white-hot fertility market
Desperate wannabe parents are betting their life savings on unproven treatments and false promises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results